---
title: "Vaxart (NASDAQ:VXRT) Stock Passes Below 200-Day Moving Average of $0.91"
description: "Vaxart, Inc. (NASDAQ:VXRT) stock has crossed below its 200-day moving average of $0.91. The company's fifty-day moving average is $0.76 and its 200-day moving average is $0.91. Vaxart reported earning"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/208321705.md"
published_at: "2024-07-09T08:22:15.000Z"
---

# Vaxart (NASDAQ:VXRT) Stock Passes Below 200-Day Moving Average of $0.91

> Vaxart, Inc. (NASDAQ:VXRT) stock has crossed below its 200-day moving average of $0.91. The company's fifty-day moving average is $0.76 and its 200-day moving average is $0.91. Vaxart reported earnings per share of ($0.14) for the quarter, beating the consensus estimate of ($0.16) by $0.02. The company has a market capitalization of $110.15 million. Several hedge funds and institutional investors have recently added or reduced their stakes in the company. Vaxart is a clinical-stage biotechnology company that develops oral recombinant protein vaccines.

Vaxart, Inc. (NASDAQ:VXRT - Get Free Report)'s share price crossed below its two hundred day moving average during trading on Monday . The stock has a two hundred day moving average of $0.91 and traded as low as $0.61. Vaxart shares last traded at $0.62, with a volume of 3,374,078 shares.

## Vaxart Stock Performance

The company's fifty day moving average is $0.76 and its 200-day moving average is $0.91. The company has a market capitalization of $110.15 million, a PE ratio of -1.18 and a beta of 0.65.

Vaxart (NASDAQ:VXRT - Get Free Report) last released its earnings results on Monday, May 13th. The biotechnology company reported ($0.14) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.16) by $0.02. Vaxart had a negative net margin of 920.00% and a negative return on equity of 121.06%. The company had revenue of $2.18 million during the quarter. On average, sell-side analysts expect that Vaxart, Inc. will post -0.55 EPS for the current fiscal year.

## Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Kingswood Wealth Advisors LLC bought a new position in Vaxart in the 1st quarter worth approximately $32,000. PFG Investments LLC bought a new position in Vaxart in the 1st quarter worth approximately $38,000. Beacon Capital Management LLC boosted its stake in Vaxart by 369.9% in the 4th quarter. Beacon Capital Management LLC now owns 50,814 shares of the biotechnology company's stock worth $29,000 after purchasing an additional 40,000 shares during the period. Tidal Investments LLC bought a new position in shares of Vaxart during the 1st quarter valued at approximately $56,000. Finally, Vanguard Group Inc. boosted its position in shares of Vaxart by 19.9% during the 1st quarter. Vanguard Group Inc. now owns 8,449,362 shares of the biotechnology company's stock valued at $10,984,000 after acquiring an additional 1,404,391 shares during the last quarter. 18.05% of the stock is currently owned by institutional investors.

## Vaxart Company Profile

(Get Free Report)

Vaxart, Inc, a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions.

## Read More

-   Five stocks we like better than Vaxart
-   Uptrend Stocks Explained: Learn How to Trade Using Uptrends
-   Don’t Miss These Stock Picks for the Lumber Price Surge
-   What is Short Interest? How to Use It
-   NVIDIA Stock Defies Skeptics, Earns Analyst Upgrade
-   The 3 Best Blue-Chip Stocks to Buy Now
-   3 Highly Profitable Companies Set for Double-Digit Upside

*This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.*

→ Kiss of death from Joe Biden (From Porter & Company) (Ad)## Should you invest $1,000 in Vaxart right now?

Before you consider Vaxart, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Vaxart wasn't on the list.

While Vaxart currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

### Related Stocks

- [VXRT.US - Vaxart](https://longbridge.com/en/quote/VXRT.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Vaxart 报告口服诺如病毒疫苗在哺乳期女性中的一期试验结果呈现积极效果 | Vaxart Inc. 报告了其口服双价诺如病毒疫苗在哺乳期女性中的积极一期临床试验结果。该双盲、安慰剂对照试验显示疫苗安全且耐受性良好，显著增加了血清和母乳中的诺如病毒特异性抗体。值得注意的是，在母乳喂养的婴儿粪便中发现了 IgA，表明被 | [Link](https://longbridge.com/en/news/272701495.md) |
| Vaxart 的高管将出席全球生物创新论坛并发表演讲 | Vaxart Inc.是一家专注于口服疫苗的生物技术公司，将于 2026 年 1 月 13 日在全球生物创新论坛上进行演讲。首席执行官 Steven Lo 和首席医学官 James F. Cummings 等关键高管将在此次虚拟活动中发言。 | [Link](https://longbridge.com/en/news/271982696.md) |
| Vaxart 将其总部和实验室迁至南旧金山内部 | Vaxart Inc. 将因租约于 2026 年 5 月 15 日终止而将其总部和实验室从南旧金山的 170 Harbor Way 迁出。此次搬迁是公司持续成本削减努力的一部分，他们计划在南旧金山地区寻找另一处办公室 | [Link](https://longbridge.com/en/news/270997244.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.
